Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35102476)
Watch
English
The new and evolving pharmacotherapy of schizophrenia
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
The new and evolving pharmacotherapy of schizophrenia
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
main subject
pharmacotherapy
0 references
schizophrenia
1 reference
based on heuristic
inferred from title
author name string
Robin Emsley
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
Piet Oosthuizen
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
publication date
1 March 2003
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
published in
Psychiatric Clinics of North America
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
volume
26
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
page(s)
141-163
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
issue
1
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
cites work
The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone in the treatment of schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of negative symptoms in schizophrenia with amisulpride
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus other atypical antipsychotic medication for schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early versus delayed initiation of progressive enteral feedings for parenterally fed low birth weight or preterm infants
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine for schizophrenia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Quetiapine for schizophrenia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molindone for schizophrenia and severe mental illness.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sertindole for schizophrenia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Drug treatment of the negative symptoms of schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus haloperidol on secondary memory: can newer medications aid learning?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of risperidone on affective symptoms in patients with schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of risperidone on hostility in schizophrenia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The new atypical antipsychotics: a review of pharmacoeconomic studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine versus haloperidol treatment in first-episode psychosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0193-953X(02)00016-3
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
PubMed ID
12683264
1 reference
stated in
Europe PubMed Central
PubMed ID
12683264
retrieved
6 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit